CARB-X funds US-based Facile Therapeutics to further develop a new oral drug that would disable toxins that enable C. difficile infections to recur. CARB-X…
CARB-X will support US-based Day Zero Diagnostics with $6.2M. The company combines whole-genome sequencing and machine learning to identify a pathogen and its drug-resistance…
Until 25th August companies, institutions and individuals are invited to submit data on their products that are in the preclinical pipeline. The data submitted…
Faced with antibiotic resistance, pharmaceuticals and governments could be doing much more, warns Manica Balasegaram, Executive Director of GARDP, in an interview with French magazine Le Temps.…
The Global AMR R&D Hub’s Dynamic Dashboard continuously collects and presents information on AMR R&D investments, products in the pipeline and push and pull…
For the first time, scientists from Jena succeeded to cultivate and functionally characterize a total of 79 bacteria strains, which had previously received little…
A new EU report sees only slow progress in the fight against AMR. The BEAM Alliance urges for more support for SMEs. Although some…
A drug combo breaking antibiotic resistance of Gram-negative priority pathogens has been selected under the ENABLE programme of the Innovative Medicines Initiative (IMI). Efficacy…
Despite challenging markets new players are entering the field to advance drug development in the fight against antimicrobial resistance. It is already a widely…